

Malignant pleural mesothelioma patients' experience by gender: findings from a cross-sectional UK-national questionnaire

Michaela Senek,¹ Steve Robertson,¹ Liz Darlison,² Lorraine Creech,² Angela Tod¹

To cite: Senek M, Robertson S, Darlison L, et al. Malignant pleural mesothelioma patients' experience by gender: findings from a cross-sectional UK-national questionnaire.

BMJ Open Resp Res
2022;9:e001050. doi:10.1136/bmjresp-2021-001050

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2021-001050>).

Received 9 July 2021

Accepted 5 January 2022

ABSTRACT

Objectives Malignant mesothelioma is an aggressive malignancy of mesothelial surfaces, most commonly those of the pleura. The aim of this study was to understand, using a national questionnaire, the gendered care experiences of patients with malignant pleural mesothelioma (MPM).

Patients were asked about their experience of the diagnostic process, about information clarity, health care professionals' knowledge, general practitioner support and overall satisfaction with care received.

Setting Recruitment of patients was carried out in three UK countries (England, Wales and Scotland) via mesothelioma clinical nurse specialists.

Participants In total, 503 patients completed the questionnaire. 460 had MPM, the remainder had other types of mesothelioma. In accord with the study protocol, only the MPM patients were included in this study. Primary and secondary measures were: (1) time from symptom to diagnosis, (2) satisfaction with the diagnosis and treatment, and (3) quality of life and well-being.

Results There were gender differences in time from symptom to diagnosis. The time from symptom to diagnosis was significantly longer for women than men (median=152 days vs men=92 days, p=0.01). Lack of a verified source of exposure to asbestos was a hindrance to private treatment access for women (95% of those that access private treatment are men). Patients were five times more likely to be satisfied if they thought that the doctors knew enough about their condition (OR=4.4, p=0.001) and nearly three times more likely to be satisfied if information was presented in a sensitive way (OR=2.8, p=0.01).

Conclusions This study has several implications for clinical practice. Our findings suggest that the diagnostic time in women might be reduced by reviewing diagnostic processes including occupational history taking, and by revising the occupational risk of mesothelioma categorisation.

Key messages

- Are there gender differences in the malignant pleural mesothelioma patients' experience of the diagnosis and the treatment process?
- By reviewing diagnostic processes, including occupational history taking, and by reviewing the occupational risk of mesothelioma categorisation, gender differences may be reduced. This would benefit women, who are currently, based on our findings, disadvantaged.
- The article explains where in the care pathway the gender differences are most significant.

although Australia and Italy also rank highly in terms of the number of cases per capita.¹ In the UK, there are approximately 2500 new cases registered in a year.²

In the UK, the source of exposure can be working in occupations where there is direct handling of asbestos, such as construction-related occupations, or from environmental exposure. The latter is mainly by exposure to low-levels of asbestos that is present in older buildings. In the UK, the Control of Asbestos Regulations 2012 recommend that asbestos should be maintained in-situ rather than removed (HSE 2020). Leaving asbestos in situ reduces the risk of fibres becoming airborne and can therefore help reduce asbestos exposure. However, this also means that the potential problem is deferred until a later date as buildings deteriorate over time.

The majority of cases of MPM arise in the pleura, this proportion being nearly 90% in the UK, with the bulk of the remaining 7%–10% arising in the peritoneum.³ A geographical analysis of MPM deaths in the UK between 1968 and 2001 showed a higher prevalence in industrial areas, such as those with a preponderance of shipyards. An analysis by occupation suggested that asbestos



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Division of Nursing and Midwifery, School of Health Sciences, The University of Sheffield, Sheffield, UK

²Mesothelioma UK, Leicester, UK

Correspondence to
Dr Michaela Senek;
m.senek@sheffield.ac.uk

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a cancer caused by exposure to asbestos, a naturally occurring mineral. Globally, the incidence of MPM has risen steadily over the past decade. It is highest in the USA and UK,



exposure in the construction industry accounted for a substantial proportion of MPM deaths.⁴

In the UK, in 2017, 83% of all cases were in men and 17% in women.⁵ The prognosis is poor with an overall survival rate of 7% after 5 years although survival rates are higher in women than men.⁶ These gender differences are thought to result from men's greater occupational exposure to asbestos (direct handling compared with women's environmental exposure) and perhaps to some physiological protection afforded to women against the disease by circulating hormones.⁷ Further studies have also shown that women who are diagnosed before the age of 45 have better survival rates than women of the same age who have been diagnosed later in life.⁷

It follows that timely identification is crucial.⁸ At the time of diagnosis, patients most commonly present with symptoms such as breathlessness and chest pain.⁹ Patients' experience of diagnosis, access to tests, general practitioner (GP) support and subsequent treatment differs.¹⁰ A national audit study from 2015 in England and Wales of 8740 MPM cases showed that just under half (47%) were being referred to a specialist from their GP, 14% of patients were referred following an emergency admission to hospital and 7% after an A&E attendance, with a further 21% being referred from a consultant in a non-respiratory specialty.¹¹

A recently published study by Senek and Steve Robertson found variations in time from symptom to diagnosis. It showed that it takes longer for women to be diagnosed with MPM than men.¹² It also suggested that most of the asbestos exposure in women was by means of indirect occupational exposure in ageing buildings such as schools, hospitals and shops.¹² These occupations are traditionally viewed as having a low risk of exposure to asbestos. The emphasis on high-risk occupations, such as construction the industry, may have masked the occupational risk to individuals who experience a low-level exposure in deteriorating buildings. This emphasis may affect the duration of the diagnostic process as, for example, the taking of patients' histories will depend in part on health professionals' understanding of occupational risk. The study recommended that further research is needed into the real-time risk of such exposure, as well as raised awareness among health professionals.¹²

Other studies that have explored the care pathway, including a systematic review, have found that receiving the diagnosis is psychologically difficult and challenging for patients.⁹ Due to poor prognosis and limited treatment options, many are left with a feeling of hopelessness and depression.¹³ A recent qualitative study by Taylor *et al*, produced a set of recommendations for healthcare professionals to improve patient experience of diagnosis.¹⁰ The main findings highlighted the importance of honesty and timeliness in communication. The main deficiencies were linked to a lack of suitable environment, insufficient time allocation and a lack of appropriate training. In this study, we will explore patients' experience of the care pathway based on self-reported

outcomes from the national Mesothelioma, Outcomes, Research and Experience (MORE) survey as well as exploring gender differences (see online supplemental appendix 1).

METHODS

Source of data

Recruitment and data collection were carried out in May 2019 by the 25 mesothelioma clinical nurse specialists across the UK who shared the questionnaire with MPM patients via a mailing list and in face-to-face clinics. This ensured that at least 70% of all UK patients with MPM at that time were invited to take part in the study. In addition, a link to the questionnaire was shared via social networking groups and the Mesothelioma UK website. Respondents were asked about their experiences of the diagnostic process, time from symptom to diagnosis and treatment satisfaction. The questions concerned:

- ▶ Clarity (whether the information they received was understandable).
- ▶ Sensitivity (whether it was given in a sensitive way).
- ▶ Healthcare professionals' knowledge (whether the doctors knew enough about the condition).
- ▶ GP support (whether enough support was received from your GP).
- ▶ Overall satisfaction with care received.

In addition, there were questions about treatment experience which mainly concerned symptom management. In addition to these questions a quality of life (QoL) validated tool (EQ5D) was included.

The participants completed the survey remotely online. The medical sections of the survey were then validated by a specialist nurse. Next, the data were anonymised and shared with the University of Sheffield research team via a double-password-encrypted file.

Patient and public involvement

As this was a secondary data analysis, we could not manipulate the study design, data collection processes and questionnaire design. However, the analysis was informed by discussions and interviews with patients in the Gendered Experience of Mesothelioma Study.¹⁴ The analysis was also informed by the conversations and analysis of the Asbestos Support Group HASAG data set, which was published in 2020.¹²

Data sharing agreement

A data sharing agreement was set up between Mesothelioma UK and the University of Sheffield. Mesothelioma UK shared the double-password-encrypted data set via a password-protected server that could only be accessed by the research team.

Data analysis

Statistical analysis explored (1) gender differences in the population of MPM patients and (2) the relationship

between type of exposure, occupational categories and time from symptom to diagnosis between genders. Missing gender data was reported as 'missing'. Gender differences were also explored in relation to satisfaction with the diagnostic and treatment process as well as its relationship with QoL and symptom management. Statistical analysis was carried out in SPSS V.26. The Shapiro-Wilk test was used to assess the normality of data. For data where normal distribution could not be assumed, descriptive statistics were expressed as medians and IQRs. The Mann-Whitney U test was used to compare non-parametric data. A probability value below 0.05 ($p<0.05$) was considered to be statistically significant. Logistic regression was carried out to determine factors that affect satisfaction with the diagnosis.

RESULTS

In the MORE data set, there were 503 pleural and peritoneal mesothelioma cases, out of which were 460 MPM cases that were included in this analysis. The sample included patients from three UK countries: England 89.1% (n=410), Scotland 5.7% (n=26) and Wales 2.4% (n=11). There were 13 cases (2.8%) that did not provide their location. There were 376 (81.7%) men and 81 (17.6%) women and three cases that did not report gender. The gender distribution was consistent with the National Mesothelioma Audit for the period 2016–2018, in which 82% of patients were male and 18% were female (Royal College of Physicians, 2020). There was a significantly higher percentage of women below the age of 65 (25.9% compared with men 18.1%), $p=0.05$. Table 1 summarises patient's age by gender.

The subtypes of MPM were epithelioid (78.9%, n=362), mixed biphasic (8.5%, n=39), unspecified (7%, n=32), sarcomatoid (5.7%, n=26). The majority of the patients in the data set (47%) were categorised by a healthcare professional as being at a tumour stage that was unsuitable for surgery, 43.9% were categorised as suitable for surgery, and 9.1% were not staged. More men than women were categorised as suitable for surgery (45.4% vs 37%). Surgery is not a standard form of treatment; however, the study participants were assessed as either suitable or not suitable for a surgery. The assessment took into account whether disease is confined (suggesting earlier stage),

Table 1 Patients' age by gender

Age	Men	Women
50 or less	N=3 (0.8%)	N=3 (3.7%)
51–55	5 (1.3%)	N=3 (3.7%)
56–60	N=15 (4%)	N=3 (3.7%)
61–65	N=45 (12%)	N=12 (14.8%)
	*18.1%≤65	*25.9%≥65
66–70	N=77 (20.5%)	N=14 (17.3%)
70+	N=230 (61.3%)	N=46 (56.8%)

subtype, patients' comorbidities and general health and fitness.

Satisfaction throughout the diagnostic process

In the sample, 80% of patients reported that they were satisfied with the diagnostic process compared with 20% (n=92) that reported that they were dissatisfied (table 2). Patients were also asked about how understandable, knowledgeable, and sensitive the diagnostic process was. They were also asked about perceived GP support available as well as overall satisfaction with the process and the healthcare professionals. The highest dissatisfaction rate (55.9%) was with patients' experience with their GP. This was followed by more than one in three (38.3%) stating that their diagnosis was not presented in an understandable way.

There were no statistically significant differences between men and women in terms of satisfaction and overall experience throughout the diagnostic process (table 2).

Factors that correlate with the level of satisfaction with the diagnosis

There were relatively low levels of correlation between Health Professionals' level of knowledge ($r=0.377$) and their sensitivity ($r=0.269$), the overall satisfaction of the diagnostic process and lower levels between understandability ($r=0.217$), multi-disciplinary team case review ($r=0.161$) and GP support ($r=0.1$).

A logistic regression analysis showed that the factor having the biggest impact on satisfaction throughout the diagnostic process was the perceived level of HPs' knowledge,¹ $p=0.001$, OR=4.43. The second most impactful factor was whether patients perceived that the diagnosis was delivered in a sensitive way ((1), $p=0.01$, OR=2.81) followed by the number of times that patients had to see their GP ((1), $p=0.039$, OR=2.166). Respondents were nearly 4.5 times more likely to be satisfied if they perceived that health professionals were knowledgeable about their conditions (OR=4.4) and nearly three times more likely to be satisfied if the diagnosis was delivered in a sensitive way (OR=2.8). The factors that did not significantly impact patient satisfaction were whether the diagnosis was understandable ($p=0.69$) or whether a multidisciplinary team had reviewed their case ($p=0.76$).

Time from symptom to diagnosis

Time from first symptom to diagnosis also differed between patients who were satisfied vs those not satisfied with the diagnostic process. Those patients that reported feeling overall satisfaction with health professionals during the diagnostic process also reported a significantly shorter time from first symptom to diagnosis (median=91, IQR=61–92 days vs median=122 days, IQR=91–123, $p=0.05$).

**Table 2** Summary table of the diagnostic experience

		MPM diagnostic process		
	No	Yes	X ² , p value	Total
Was the explanation of the mesothelioma diagnosis understandable	176 38.30% (44.4% women, 37.1% men)	283 61.70%	(1)=1.548, 0.257	459
Was the explanation given in sensitive way	126	332	(1)=0.638, 0.681	458
Sensitivity	27.50% (29.6% women, 26.7% men)	72.50%		
Were you told that a multidisciplinary team had reviewed your case.	106 29.80% (32.7% women, 22.3% men)	250 70.20%	(1)=1.498, 0.148	356
Did healthcare professionals have sufficient knowledge and know enough about your condition	115	344	(1)=0.786, 0.778	459
Knowledge	25.10% (26.3% women, 24.7% men)	74.90%		
Did you receive good support from your GP in relation to your diagnosis	252	199	(1)=0.675, 0.727	451
GP support	55.90% (54.8% women, 55.1%)	44.10%		
Were you overall satisfied with healthcare professionals during your diagnosis	92	364	(1)=0.845, 0.857	456
Overall satisfaction	20.20% (21.5% women and 19.8% men)	79.80%		

GP, general practitioner; MPM, malignant pleural mesothelioma.

Time from symptom to diagnosis by occupation and gender

Respondents were asked the following questions relating to their asbestos exposure: (1) From your memory were you ever exposed to asbestos? In the sample, 76.4% of men responded 'Yes, through my work', compared with only 28.9% of women and, (2) 'If exposed at work, what was your occupation at the time'. Occupation and source of exposure were then categorised into direct handling versus environmental exposure occupations. Builders, electricians, carpenters, liggers and plumbers were combined into Direct handling category (direct handling of asbestos at work) and teachers, doctors, nurses', administrative staff and secretarial staff were combined into Working Environment category.

Furthermore, 18.6% of women compared with 3.9% of men reported that they had been exposed via their partners, for instance by washing their clothes. This has been reported in previous literature.⁶ In our sample, the time from symptom to diagnosis was significantly longer for women than men (median=152 days vs men=92 days, p=0.01).

There were no women in the occupational categories where there is direct handling of asbestos, therefore we

could not directly compare the time from symptom to diagnosis in this category. However, a comparison of the time from symptom to diagnosis in the did not know where they had been exposed/no occupation category between women and men showed that it took significantly longer for women to be diagnosed (151 days) compared with men (91 days; IQR=55–80, p=0.05) (see table 3).

The women who reported knowing that they had been exposed at work had mainly been exposed via their working environment as opposed to via direct handling of asbestos. The way that the question was phrased may be problematic to the analysis of this data because they were only asked to list their occupation if they knew/had proven that they had been exposed at work. This question may be problematic because in the cases of environmental exposure it is more difficult to know/prove that this was the case. Therefore, in future cases, occupation data should be collected from all patients.

Satisfaction throughout the care pathway

In the patients questioned, the majority (59.8%, n=275) travelled to a different hospital for treatment from the

Table 3 Occupational category and time from symptom to diagnosis

Occupation/source of exposure, time from symptom to diagnosis (median, days)	Men	Women	P value
Construction (builder, electrician, plumber, carpenter, lagger)	49.6%, (N=188), 92 days, IQR=50–81	There were no women in this category.	Not applicable
Work environment (teacher, doctor, nurse, secretarial, admin)	2.6%, (N=10), 97 days, IQR=35–90	17.3%, (N=14), 396 days, IQR=58.75–80.75	0.47
No occupation listed because assumed/could not prove that was exposed at work	24% (N=91), 90 days, IQR=50–77.5	67.9%, (N=55), 151 days, IQR=60–80	0.076
Other	23.7%, (N=90), 92 days, IQR=50.75–85	14.8%, (N=12), 169 days, (IQR=80–95.25)	0.05*

*Significant.

one in which they had been diagnosed, while 38.9% (n=179) of patients were both diagnosed and treated in the same hospital. Out of the patients that were referred to another hospital, 28% (n=129) received all their care in that same hospital, while 17.2% (n=79) shared care between hospitals. The majority of the patients (94.6%) reported that the appointments with the doctor and/or medical team were frequent enough. In terms of outpatient appointments, 83% of patients thought that it was easy/fairly easy to make an appointment, 4% found it difficult and 13% did not know/could not remember.

Private treatment by gender expected/received

More than one in five patients (23.3%, n=107) reported that they had, or will be, expected to pay for private treatment. Out of the 107 (23.3%), that reported this, only 11% were women (n=12).

Private treatment by gender received

Nearly 62.6% (n=67) reported that they had already had their non-National Health Service (NHS)-funded treatment costs covered as part of their legal claim. Out of the 67 cases (62.6%) that had their non-NHS funded treatment costs covered, the majority were men (95%, n=64). Only 3.7% (n=3) of women reported that they already had their additional private treatment costs covered as part of their legal claim compared with 95% (n=64) of men ($p=0.01$).

Treatment type and QoL

In this patient cohort, 75.9% had chemotherapy, 16.5% had surgery, 10.9% immunotherapy, 9.1% had radiotherapy, 8.5% had no treatment and 1.8% had targeted therapy. A Quality-of-Life score was assessed using the 0–100 EuroQoL-5D instruments scale. Patients that had surgery reported the highest QoL score (71.6). Self-reported QoL for those who only had chemotherapy was 67.2, radiotherapy QoL=65, immunotherapy QoL=69, no treatment QoL=61.8. However, a comparison by gender showed different QoL by treatment scores (see table 4)

Respondents were asked to rate their overall QoL and well-being using the EQ5D scale. QoL score was only

slightly higher in the group that reported satisfaction with overall treatment (IQR 70 vs 68, $p=0.2$). The median QoL score was significantly higher among women (women QoL=74, men QoL=70, $p=0.04$).

Satisfaction with the treatment most strongly correlated with the perception that HPs have sufficient knowledge of their condition ($r=0.42$), management of fatigue ($r=0.28$), pain management ($r=0.24$), cough management (0.23), and breathlessness ($r=0.22$). All correlations were significant ($p<0.01$) (see table 5).

Mental health

Respondents were also asked to rate their level of anxiety and depression, as either not, slightly, moderately, extremely or severely depressed. There were no differences between men and women (81.4% women vs 81.2% of men) that had no or slight problem with depression and anxiety. The proportion of moderately depressed was also similar (15.8% of men vs 16% of women). There were proportionately more men (2.4% vs 1.2% women) that reported extreme to severe anxiety and depression levels.

DISCUSSION

This study provides new insights into MPM patients' experiences in relation to gender, satisfaction with diagnosis

Table 4 Quality of life (QoL) score by treatment type received

Treatment received	Men Median, IQR QoL Score	Women median, IQR QoL Score	Satisfaction rate with treatment
Surgery	75	77.5	83.9%
Chemotherapy	70	70	86.9%
Radiotherapy	60	68.5	81.1%
Immunotherapy	75	70	92.7%
Targeted therapy	67.8	82.5	75%
None	60	67	85%

**Table 5** Patients' experience of the treatment

Treatment-related question	MPM treatment process		
	Yes (%)	No (%)	Total
Satisfaction with treatment (yes/no)* Overall have all the professionals involved in your treatment worked well together to provide the best possible care?	(n=380) 83.7% Women=85.9% Men=83.2%	(n=74) 16.3% Women=14.1% Men=16.8%	Total=460 N=4 chose not to say
Perception that health professionals had sufficient knowledge (yes/no) Do you think that the doctors treating mesothelioma knew enough about the condition and treatment?*	(n=396) 86.5% Women=84.4% Men=85.7%	(n=62) 13.5% Women=15.6% Men=14.3%	Total=458 N=2 chose not to say
Breathlessness controlled (yes/no)* Did hospital doctors and nurses do everything they could to help control any breathlessness?	(n=209) 68.5% Women=71% Men=67.2%	(n=96) 38.5% Women=29% Men=32.8%	Total=305 N=153 did not have this symptom
Fatigue controlled (yes/no)* Did hospital doctors and nurses do everything they could to help control any fatigue?	(n=154) 53.1% Women=49.2% Men=53.9%	(n=136) 46.9% Women=50.8% Men=46.1%	Total=290 N=168 did not have this symptom
Coughing controlled* Did hospital doctors and nurses do everything they could to help control any coughing?	(n=103) 53.3% Women=52.8% Men=52.4%	(n=94) 47.7% Women=47.2% Men=47.6%	Total=197 N=261 did not have this symptom
Pain controlled* Did hospital doctors and nurses do everything they could to help control any pain?	(n=218) 77.6% Women=71.1% Men=78.8%	(n=63) 22.4% Women=28.9% Men=21.1%	281 N=177 did not have this symptom

*None of the treatment processes were statistically significantly different between men and women.

MPM, malignant pleural mesothelioma.

and treatment, time from symptom onset to diagnosis, source of exposure/occupation and QoL.

Our study population contained proportionally more men than women with MPM. However, the proportion of younger women was greater than that of younger men (26% of women compared with 18.1% of men were 65 years or younger). This finding corresponds to the national figures.⁵

The results suggest that women were disadvantaged during the time of diagnosis, which was significantly longer compared with men. This echoes previous findings of a study based on a cohort of MPM patients in South of England¹² which showed that it took longer for women to be diagnosed. In MPM, men are often diagnosed sooner, possibly because the disease is more common in men and because there is a higher awareness among healthcare professionals of the risk of mesothelioma for those in direct handling occupations. In our sample, there were no women that were in the direct handling occupational category. Aligning with the findings in Senek and Steve Robertson, in our sample of working women, the occupational risk was more likely to be linked to indirect exposure in a contaminated work environment, rather than to the direct handling of asbestos. Occupational differences between men and women with MPM thus have implications for healthcare staff. To improve the diagnosis of MPM, insight is needed into how occupational histories are taken in healthcare settings. Furthermore, patients who experience a diagnostic delay may require additional support in coming to terms with the diagnosis

and the fact that it has been delayed. Ball *et al* have shown that, if diagnostic delay is not addressed appropriately, it can have detrimental psychological effects on patients.⁹

Most patients (80%) reported that they were satisfied with the diagnostic process. However, those that were dissatisfied had a significantly longer time from symptom to diagnosis. This suggests that the time it takes to be diagnosed leads to dissatisfaction. During the diagnostic period, the highest proportion of dissatisfaction (55.7%) was with support received from their GP. However, patients were most likely to be satisfied if the diagnosis was delivered sensitively (OR=4.4, p=0.001) and if they felt that the HP was knowledgeable (OR=2.8, p=0.01). A high proportion of patients also reported that their diagnosis was not understandable (38.3%) but this factor was not as important as the sensitivity and knowledge of HPs.

There is a need for training in taking extended asbestos exposure history and occupational exposure among HPs. A comprehensive history is essential to the diagnostic process as HPs are unlikely to suspect the disease unless a patient describes a job where asbestos exposure may have occurred. Mesothelioma is a rare disease with similar symptoms to more common and less severe conditions. At present, it is sometimes confused for a different illness or another type of cancer, such as pneumonia or lung cancer.

The highest QoL score was among those patients that had surgery as part of their treatment. However, this may be due to the overall selection bias, as fitter patients are likely to have a higher QoL prior to treatment. Therefore,

their overall QoL score may have made them eligible for surgery in the first place. Women reported a higher overall QoL score.

In our sample, women were less likely to have additional private treatment. This may be due to the costs involved and because they are significantly less likely to have the costs of additional non-NHS-funded treatment covered by a compensation settlement. So far, no data has been collected at a national level on intention to seek legal advice, and actions subsequently taken, to compare differences between men and women.¹⁵ A previous study by Senek and Steve Robertson, based on mesothelioma cases from South of England, showed that women were less likely to apply for compensation.¹² This may be explained by the higher awareness of the association between some occupational categories and asbestos-related diseases. In our study, women's occupational exposure was more often linked to indirect exposure in the work environment than to the direct handling of asbestos. These occupations are still classified as 'low-risk', (rightly or wrongly) resulting in fewer precedents for taking legal action.

Unlike Rake *et al*, this study did not find that the occupational risk in women was concentrated in industrial settings but found occupational risk in office-based work environments.⁶ It suggests that a long term, low-level exposure may be causing an increase in mesothelioma cases among people working in occupations that have previously not been noted as particularly risky. This is in line with previous research indicating that mesothelioma can develop from long-term exposure to low concentrations of asbestos fibres in the air.¹⁶ At present, a value of 0.01 fibres/mL is taken as the 'clearance indicator' threshold, and a site should not normally be regarded as fit for reoccupation until the asbestos in air measurements are below this level. It is noteworthy that this value is 10 times higher than that which countries like Germany, France and the Netherlands permit. Therefore, the UK may currently be underestimating the risk of low-level exposure. This theory is supported by the high proportion of mesothelioma cases among patients that had been employed in so called low-risk occupations and would suggest that long-term, low-level exposure is a concern. Therefore, more emphasis is required on the risk associated with long-term, low-level indirect exposure resulting from working in asbestos-contaminated buildings. This recognition would be of particular benefit to women.

Strengths and limitations

This is the first study to explore the experience of MPM patients by gender in three UK countries. The study participants were from all but one of the four UK countries (there were no Northern Ireland cases). The study population can be considered to represent patients with MPM across most of the UK and results can be extrapolated at national level. The data, however, did not include information on potential exposure to asbestos in

childhood, previous medical history, exact geographical location and whether patients' partners had been working in a high-risk area. Such data could potentially identify other sources of exposure given that certain geographical locations and exposure through a partner are known sources. The data set did not include any information on patients' disease progression or survival rates, which would have been additional indicators of quality of care received. Furthermore, in our data set, the proportion of respondents that had active treatment was higher than the proportion reported in the National Mesothelioma Audit. This is a potential limitation of the study. It may be that, unknowingly, a group biased towards those of better performance status and less advanced disease was sampled.

Implications for practice

This study has several implications for clinical practice, in particular regarding diagnostic processes and patient support. In the study, it took longer for women to be diagnosed than for men. The reason for this gender-based delay in diagnosis is unknown. In MPM, men are often diagnosed quicker, possibly because it is more common in men and the fact that healthcare professionals may take a more detailed or accurate occupational history for men than for women due to the varying awareness of risk of mesothelioma according to occupation and/or gender. Occupational differences between men and women are not merely a legal issue, but also have implications for healthcare staff. To improve the diagnosis of MPM, it could be beneficial to review the diagnostic process in order to determine the cause of delay, particularly for women.

The HP's level of sensitivity and knowledge were significant determinants of patient satisfaction. Consideration could therefore be given as to how this can be improved for the large proportion of patients that felt that this was lacking. This further highlights the importance of early referral and signposting to services that have more expert knowledge and experience in treating and caring for those with mesothelioma.

HPs need to be more alert to a diagnosis of MPM in both men and women who have no history of direct exposure to asbestos. To address the delays and gender differences in the care pathway, it is important that HPs are better informed regarding the age and types of exposure in women. However, for unexplained reasons women in this category have a longer symptom to diagnosis period than men. Awareness around the importance of communication skills and better knowledge among HPs could be further improved by all stakeholders, including national societies and cancer charities. In addition, the delayed diagnosis and prolonged care pathway could be addressed in at least two ways: first, by means of implementation of Getting it Right the First Time Cancer recommendations and, second, through a dedicated suspected-mesothelioma pathway for GP referrals,



separate from the lung cancer pathway, to ensure rapid referral to a pleural service. Patient experience might also be improved through better signposting to clinical nurse specialists across the three UK countries.

CONCLUSION

The study provides new insights into gender differences in mesothelioma regarding time from symptom onset to diagnosis and patients' experiences. The care of patients with mesothelioma can be improved—and gender differences can be reduced—by reviewing diagnostic processes, including occupational history taking and by reviewing the occupational risk of mesothelioma categorisation. It may be beneficial to raise awareness among healthcare professionals who are the first point of contact at first presentation of symptoms, such as GPs.

Contributors LC and LD collected the data. MS designed the study and carried out all analysis. MS wrote the paper. AT and SR contributed to the analysis and the write up of the paper. The corresponding author (MS) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. MS is the author acting as guarantor.

Funding This project was funded by Mesothelioma UK as part of a portfolio of research conducted by the Mesothelioma UK Research Centre-Sheffield (MUKRC-S). The MUKRC-S is an alliance between the Mesothelioma UK and the University of Sheffield.

Disclaimer The views expressed are those of the author(s), and not necessarily those of Mesothelioma UK or University of Sheffield.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s)

Ethics approval This study involves human participants, but the University of Sheffield Ethics committee exempted this study because the data set did not include any personal or patient identifiable data.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

- Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. *Eur Respir Rev* 2016;25:472–86.
- Cancer Research UK. *Cancer research UK cancer incidence statistics*. CancerResearchUK, 2018.
- PH S. *Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas*. Cine-Med Publishers Woodbury, 2012.
- McElvenny DM, Darnton AJ, Price MJ, et al. Mesothelioma mortality in Great Britain from 1968 to 2001. *Occup Med* 2005;55:79–87.
- Physicians RC of. National mesothelioma audit report.
- Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. *Br J Cancer* 2009;100:1175–83.
- Taioli E, Wolf AS, Camacho-Rivera M, et al. Women with malignant pleural mesothelioma have a threefold better survival rate than men. *Ann Thorac Surg* 2014;98:1020–4.
- Stahel R, Bosco EF, Opitz I. Mesothelioma. In: *Lung cancer therapy annual*, 2008.
- Ball H, Moore S, Leary A. A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer. *Eur J Oncol Nurs* 2016;25:62–7.
- Taylor BH, Warnock C, Tod A. Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience. *BMJ Open Respir Res* 2019;6:e000413.
- Warby A, Dhillon HM, Kao S, et al. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma. *Support Care Cancer* 2019;27:3509–19.
- Senek M, Steve Robertson AT. Mesothelioma: exploring gender differences in time to diagnosis, seeking legal advice and occupational risk. *Cancer Nurs Pract* 2020.
- Arber A, Spencer L. 'It's all bad news': the first 3 months following a diagnosis of malignant pleural mesothelioma. *Psychooncology* 2013;22:1528–33.
- Ejegi-Memeh S, Robertson S, Taylor B, et al. Gender and the experiences of living with mesothelioma: a thematic analysis. *Eur J Oncol Nurs* 2021;52:101966.
- Marinaccio A, Gariazzo C, Di Marzio D, et al. Predictors of filing claims and receiving compensation in malignant mesothelioma patients. *Health Policy* 2020;124:1032–40.
- Morrin M, Jack Aldane HK. Don't breathe in: Bridging the Asbestos Safety Gap [Internet], 2019. Available: <https://www.respublica.org.uk/wp-content/uploads/2019/11/Asbestos-Report-Final.pdf>



Mesothelioma Outcomes, Research and Experience survey (MORE Survey).

Mesothelioma UK would like to invite mesothelioma patients to have the opportunity to describe what their experience of investigations, treatment and care has really been like.

The survey will enable Mesothelioma UK to inform health care providers about what is being done well, what could be improved and hopefully where there are variations in treatment and care. It will also assist Mesothelioma UK to develop its services to complement those of the NHS. Mesothelioma UK will make recommendations representing the patient experience and circulate these to the wider mesothelioma community and health care providers

Thank you for taking the time to complete the survey. I confirm that any details that you give on the survey will be completely anonymised.

Yours sincerely

Liz Darlison Head of Services

Welcome to the Mesothelioma Outcomes Research and Experience (MORE) Survey. Please complete all 3 sections and ask your MESO UK nurse to check and validate section 3 before submitting

Section 1

Information about you - your experience of care and treatment

Please enter the unique patient identifier supplied by your Meso UK nurse

Are you resident in the UK?

- Yes (*if yes, please continue*)
 No (*if no, please do not complete the study*)

Q1.1. What is the first part of your home postcode?
e.g. BS35

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
----------------------	----------------------	----------------------	----------------------

Q1.2. How old are you now?

- Under 18 46-50
 19-25 51-55
 26-30 56-60
 31-35 61-65
 36-40 66-70
 41-45 70+

Q1.3. Are you

- Male Female

Asbestos exposure

Q1.4. From your memory were you ever exposed to asbestos?

- Yes, through my own work (*please go to Q1.5*)
 Yes, through another person's work
e.g. laundering clothing
 Yes, my house contained asbestos e.g. whilst undertaking DIY
 Yes, by living near to the asbestos industry
 Don't know

Q1.5. If exposed at work, what was your occupation at that time?

- I was not or don't think I was exposed at work
 Joiner or carpenter
 Electrician
 Plumber
 Builder
 Lagger
 Teacher
 Nurse
 Doctor
 Engineer
 Secretarial or Admin
 Other

Q1.6. Is there a history of mesothelioma in your family?

- Yes No Don't know

Q1.7. Since being diagnosed with Mesothelioma were you ever helped to identify where the asbestos exposure may have occurred?

- Yes No

Q1.8. Have you ever been a member of the armed forces?

- Yes (*if yes, please go to Q1.9*)
 No (*if no, please go to Q1.11*)

Q1.9. If you have been a member of the armed forces which service?

- Army
 Royal Navy
 Royal Airforce
 Other

Q1.10. If you have been a member of the armed forces what was your length of service?

- Less than 5 years
 5-10 years
 10-15 years
 15-20 years
 More than 20 years

Medical History

Q1.11. To the best of your ability, can you recall the approximate date when you first experienced symptoms relating to your mesothelioma?

- Yes (*if yes, please go to Q1.12*)
- No (*if no, please go to Q1.13*)

Q1.12. Date when first experienced symptoms

Please write 1st of month and year

Q1.13. To the best of your ability, can you recall the date you were diagnosed with mesothelioma?

Please write 1st of month and year

Q1.14. Can you remember approximately how many times you presented to your GP with symptoms related to mesothelioma before being referred to the hospital for further tests?

- None
- 1-2
- 3-4
- 5+
- Don't know

Q1.15. In the last year, related to your mesothelioma, how many outpatient visits have you attended – ie in total for hospital visits, clinical appointments, scans, tests or treatment

- | | |
|--------------------------------|-------------------------------------|
| <input type="checkbox"/> None | <input type="checkbox"/> 16-20 |
| <input type="checkbox"/> 1-5 | <input type="checkbox"/> 20+ |
| <input type="checkbox"/> 6-10 | <input type="checkbox"/> Don't know |
| <input type="checkbox"/> 11-15 | |

Q1.16. In the last year how many hospital admissions have you had related to mesothelioma?

- None
- 1-2
- 3-4
- 5+
- Don't know

Q1.17. In the last year how many nights have you had to spend in hospital related to their mesothelioma?

- | | |
|--------------------------------|-------------------------------------|
| <input type="checkbox"/> None | <input type="checkbox"/> 16-20 |
| <input type="checkbox"/> 1-5 | <input type="checkbox"/> 20+ |
| <input type="checkbox"/> 6-10 | <input type="checkbox"/> Don't know |
| <input type="checkbox"/> 11-15 | |

Your personal experience in the management of your mesothelioma

Q1.18. Who was it that first told you about your mesothelioma diagnosis?

- GP
- Hospital doctor
- Mesothelioma nurse specialist
- Other nurse specialist
- Relative or a friend
- Nobody, I / we worked it out for ourselves
- Someone else

Q1.19. Was the explanation of the mesothelioma diagnosis given in an understandable way?

- Yes, completely
- Yes, to some extent
- No
- Don't know

Q1.20. Was the explanation given in a sensitive way?

- Yes
- Somewhat, but it could have been given more sensitively
- No
- Cannot remember

Q1.21. Did someone explain that a multidisciplinary team had reviewed your case?

- Yes
- No
- Don't know

Q1.22. Have you received all of your care and treatment at the same hospital?

- Yes, I was diagnosed and treated at the same hospital
- No, I received my treatment at another hospital

If yes, please go to Q1.24

Q1.23. If you were referred to another hospital for treatment, has all your treatment continued there?

- Yes
- No, I have returned to the hospital where I was diagnosed
- No, I have shared care between the hospitals

Q1.24. Was written information provided about treatment and side effects of treatments given to or shared with you?

- Yes, at the hospital where I was diagnosed
- Yes, at the hospital where I received my treatment (if these are not the same)
- No
- Don't know
- Can't remember

Q1.25. Were the appointments with your hospital doctor/team frequent enough? Yes No**Q1.26. If you needed to arrange an outpatient appointment how easy was it?**

<input type="checkbox"/> Very easy	<input type="checkbox"/> Very difficult
<input type="checkbox"/> Fairly easy	<input type="checkbox"/> Don't know
<input type="checkbox"/> Not very easy	<input type="checkbox"/> I can't remember

Q1.27. Do you think that the doctors diagnosing mesothelioma knew enough about the condition and treatment?

Yes
 Yes, to some extent
 No

Q1.28. Do you think that the doctors treating mesothelioma knew enough about the condition and treatment?

Yes
 Yes, to some extent
 No

Q1.29. When you have had CT scans, have you received the results in a timely manner?

Yes No

Q1.30. Did hospital doctors and nurses do everything they could to help control any breathlessness?

I haven't had this symptom
 Yes, they did
 Yes, to some extent
 No, they didn't

Q1.31. Did hospital doctors and nurses do everything they could to help control any fatigue?

I haven't had this symptom
 Yes, they did
 Yes, to some extent
 No, they didn't

Q1.32. Did hospital doctors and nurses do everything they could to help control any coughing?

I haven't had this symptom
 Yes, they did
 Yes, to some extent
 No, they didn't

Q1.33. Did hospital doctors and nurses do everything they could to help control any pain?

I haven't had this symptom
 Yes, they did
 Yes, to some extent
 No, they didn't

Q1.34. Did the doctors and the nurses give the person with mesothelioma and the family all the information needed to help care at home?

Yes, definitely
 Yes, to some extent
 Yes, to the person with mesothelioma only
 No, family and friends were not involved
 Family or friends did not need the information
 They did not want the family or friends to be given the information
 Don't know
 I can't remember
 Not applicable at present

Q1.35. Was good support received from your GP in relation to your mesothelioma diagnosis?

Yes definitely
 Yes, to some extent
 No

Q1.36. Were you informed of the name of the Mesothelioma UK Nurse, Nurse Specialist or other keyworker?

Yes, Mesothelioma UK Nurse
 Yes, other Nurse Specialist
 Yes, other keyworker
 No
 Don't know / I can't remember

Q1.37. Were you informed of a Mesothelioma UK specifically funded nurse?

Yes, my nurse specialist is a Mesothelioma UK Nurse
 Yes, I was informed by my Nurse Specialist, other keyworker
 No, I was not informed
 Don't know / I can't remember

Q1.38. How easy was it to contact your Mesothelioma UK Nurse, other Nurse Specialist or keyworker?

Very easy
 Fairly easy
 Not very easy
 Very difficult
 Don't know / I can't remember

Q1.39. Does the Mesothelioma UK Nurse, other Clinical Nurse Specialist or keyworker answer important questions in an understandable way?

Yes, completely
 Yes, to some extent
 No
 Don't know / I can't remember

Q1.40. Were you given information about self-help groups or support groups for people with mesothelioma?

- Yes
 No
 Don't know / I can't remember

Q1.41. Have you attended a patient and carer support group?

- Yes (*if yes, please go to Q1.43*)
 No (*if no, please go to Q1.42*)

Q1.42. If no, would you like to have attended a patient and carer support group?

- Yes Maybe No

Q1.43. Was enough support provided at home (for example district nurses, carers, physiotherapists or occupational therapists)?

- Yes
 Yes, to some extent
 No
 No, support at home has not been needed

Q1.44. Was support received from a community palliative care nurse (for example a Macmillan Nurse or Marie Curie Nurse)?

- Yes
 Yes, to some extent
 No
 No, this support has not been needed

Q1.45. Was support received in relation to planning care towards the end of life?

- Yes
 No
 Didn't want to discuss it
 Don't know
 I can't remember
 Not applicable at present

Q1.46. Overall have all the professionals involved in your diagnosis worked well together to provide the best possible care?

- Yes
 Yes, to some extent
 No

Q1.47. Overall have all the professionals involved in your treatment worked well together to provide the best possible care?

- Yes
 Yes, to some extent
 No

Q1.48. Has the person with mesothelioma, relative or friend ever been in contact with Mesothelioma UK via telephone, the helpline or email?

- Yes
 No
 Don't know / I can't remember

Q1.49. Were you given information about how to get financial help or benefits?

- Yes
 No
 Don't know / I can't remember

Q1.50. Have you been in contact with an asbestos support group?

- Yes
 No
 Don't know / I can't remember

Q1.51. Were you advised about how to contact a lawyer who specialises in claims for mesothelioma?

- Yes, at the time of my diagnosis
 Yes, after the time of my diagnosis
 No
 Don't know / I can't remember

Q1.52. Have clinical trials ever been discussed with you?

- Yes, at the time of my diagnosis
 Yes, during or after my treatment
 No
 Don't know / I can't remember

Q1.53. Have you ever been enrolled into a clinical trial?

- Yes (*if yes, please go to Q1.54*)
 No (*if no, please go to Q1.56*)
 Don't know / I can't remember (*If don't know, please go to Q1.56*)

Q1.54. If you have been enrolled into a clinical trial were you given enough information?

- Yes
 No
 I can't remember

Q1.55. If you have been enrolled into a clinical trial, can you say approximately how long your journey to the hospital for the trial or to receive treatment takes?

- | | |
|---|--|
| <input type="checkbox"/> less than 30 minutes | <input type="checkbox"/> 151-180 minutes |
| <input type="checkbox"/> 31-60 minutes | <input type="checkbox"/> 181-210 minutes |
| <input type="checkbox"/> 61-90 minutes | <input type="checkbox"/> 210-240 minutes |
| <input type="checkbox"/> 91-120 minutes | <input type="checkbox"/> more than 240 minutes |
| <input type="checkbox"/> 121-150 minutes | |

Q1.56. Regarding treatment for your Mesothelioma were you ever given information about obtaining a second opinion?

- Yes (*if yes, please go to Q1.57*)
- No (*if no, please go to Q1.58*)
- Don't know (*if don't know, please go to Q1.58*)

Q1.57. If you attended another hospital for a second opinion, can you say approximately how long it takes on each journey for a second opinion?

- | | |
|---|--|
| <input type="checkbox"/> less than 30 minutes | <input type="checkbox"/> 151-180 minutes |
| <input type="checkbox"/> 31-60 minutes | <input type="checkbox"/> 181-210 minutes |
| <input type="checkbox"/> 61-90 minutes | <input type="checkbox"/> 210-240 minutes |
| <input type="checkbox"/> 91-120 minutes | <input type="checkbox"/> more than 240 minutes |
| <input type="checkbox"/> 121-150 minutes | |

Q1.58. Have you been able to claim cost of travel to the hospital where you obtained a second opinion or attended due to a clinical trial?

- Yes, from the trial itself
- Yes, from Mesothelioma UK
- Yes, from another source of funding
- No, I did not want to claim it
- Not applicable

Q1.59. Has the cost of travel insurance for holidays abroad ever been an issue for you?

- Yes
- No

Q1.60. Have you or are you expecting to have to pay for any private treatment?

- Yes
- Yes and provision has been made for this as part of my legal claim
- No
- Don't know

Did you know that deaths thought to be due to mesothelioma or other asbestos related diseases are regarded as 'unnatural' and must be referred to the local coroner (procurator fiscal in Scotland) who carries out an investigation?

Q1.61. Were you or a family member informed about the role of the coroner / procurator fiscal?

- Yes
- No
- Don't know / I can't remember

Section 2

Quality of Life Assessment Questionnaire

Under each heading, please tick the ONE box that best describes your health TODAY

MOBILITY

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

SELF-CARE

- I have no problems washing or dressing myself
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

USUAL ACTIVITIES

(e.g. work, study, housework, family or leisure activities)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities


PAIN / DISCOMFORT

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

ANXIETY / DEPRESSION

- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

- We would like to know how good or bad your health is TODAY
- This scale is numbered from 0 to 100.
- 100 means the best health you can imagine. 0 means the worst health you can imagine.
- Mark an X on the scale to indicate how your health is TODAY.
- Now, please write the number you marked on the scale in the box.



Section 3

Clinical Management of Mesothelioma.
(To be validated with a clinical nurse)

Q3.1. What was the location of your tumour at diagnosis?

Tick as many as apply

- Left Pleural
- Right Pleural
- Peritoneal
- More than one place
- Other

Q3.2. What type of Mesothelioma do you have?

- Epithelioid
- Sarcomatoid
- Mixed/Biphasic
- Unspecified
- Don't know (To be validated by the nurse and classified to one of the above)

Q3.3. What was the stage of tumour at diagnosis?

- Suitable for surgery
- Unsuitable for surgery
- Suitable for surgery but I declined
- Not staged
- Don't know (nurse to fill in one of above)

Q3.4 Which of the following procedures have you previously undergone?

Tick as many as apply

- CT scan (*please go to Q3.5*)
- Ultrasound scan
- PET scan
- MRI scan
- CT guided biopsy
- Bronchoscopy Laparoscopy
- Fluid drained from the lung (*please go to Q3.6*)
- Fluid drained from the abdomen
- Permanent or indwelling drain (Pleurx/Rocket)
- Thoracoscopy with local anaesthetic, ie awake
- Thoracoscopy with general anaesthetic/asleep
- Surgical biopsy

Q3.5. Within the last year how many CT scans have you received?

- 0
- 1-2
- 3-4
- 5+

If you had fluid drained from the lung

Q3.6. How many times in total have you had fluid drained from the lung?

- 0 3
- 1 4
- 2 5+

Q3.7. Were you offered a permanent or indwelling drain?

- Yes No Don't know

Q3.8. Which of the following treatments (either in or out of a clinical trial) have you been offered but not taken?

Tick as many as apply

- Surgery
- Radiotherapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- None

Q3.9. Which of the following treatments (either in or out of a clinical trial) have you received to date?

Tick as many as apply

- Surgery (*please go to Q3.10*)
- Radiotherapy (*please go to Q3.18*)
- Chemotherapy (*please go to Q3.26*)
- Immunotherapy
- Targeted Therapy
- None

If you are currently or have previously received surgery for your mesothelioma can you provide the month and year when you received this treatment and what was it for? Q3.10 – Q3.17

Complete as many as apply

Q3.10. First surgical procedure

Please write 1st of month and year

Q3.11. What was it for?

Tick as many as apply

- Biopsy
- Biopsy and drain fluid combined
- Drain fluid
- Remove some of the tumour
- Remove all of the tumour
- Address complications of surgery
- Other

Q3.12. Have you had a second procedure?

Yes No

Q3.13. Second surgical procedure

Please write 1st of month and year

Q3.14. What was it for?

Tick as many as apply

- Biopsy
- Biopsy and drain fluid combined
- Drain fluid
- Remove some of the tumour
- Remove all of the tumour
- Address complications of surgery
- Other

Q3.15. Have you had a third procedure?

Yes No

Q3.16. Third surgical procedure

Please write 1st of month and year

Q3.17. What was it for?

Tick as many as apply

- Biopsy
- Biopsy and drain fluid combined
- Drain fluid
- Remove some of the tumour
- Remove all of the tumour
- Address complications of surgery
- Other

If you are currently or have previously received radiotherapy for your mesothelioma can you provide the month and year when you received this treatment and what was it for? Q3.18 – Q3.25

Complete as many as apply

Q3.18. First course of radiotherapy

Please write 1st of month and year

Q3.19. What was it for?

Tick as many as apply

- To prevent tumour from spreading
- To reduce a lump
- To treat area/s of disease growth
- To treat an area of disease causing pain

Q3.20. Have you had a second course of radiotherapy?

Yes No

Q3.21. Second course of radiotherapy

Please write 1st of month and year

Q3.22. What was it for?

Tick as many as apply

- To prevent tumour from spreading
- To reduce a lump
- To treat area/s of disease growth
- To treat an area of disease causing pain

Q3.23. Have you had a third course of radiotherapy?

Yes No

Q3.24. Third course of radiotherapy

Please write 1st of month and year

Q3.25. What was it for?

Tick as many as apply

- To prevent tumour from spreading
- To reduce a lump
- To treat area/s of disease growth
- To treat an area of disease causing pain

If you are currently receiving or have previously received chemotherapy for your mesothelioma can you provide the following information. Q3.26–Q3.41

Q3.26. First course of chemotherapy

Please write 1st of month and year

Q3.27. Was this as part of a Clinical Trial?

Yes No

Q3.28. What was the treatment?

- Pemetrexed and Cisplatin
- Pemetrexed and Carboplatin
- Pemetrexed as a single drug
- Pemetrexed, Cisplatin and Bevacizumab (Avastin)
- Pemetrexed, Carboplatin and Bevacizumab (Avastin)
- Bevacizumab (Avastin) as a single drug
- Gemcitabine and Cisplatin
- Gemcitabine and Carboplatin
- Vinorelbine
- Any other drugs in a clinical trial
- Any other drugs not in a clinical trial

Q3.29. How many cycles did you complete?

- | | |
|----------------------------|--|
| <input type="checkbox"/> 1 | <input type="checkbox"/> 5 |
| <input type="checkbox"/> 2 | <input type="checkbox"/> 6 |
| <input type="checkbox"/> 3 | <input type="checkbox"/> More than 6, still receiving it |
| <input type="checkbox"/> 4 | |

Q3.30. Did you continue on maintenance treatment?

- Yes No

Q3.31. Did you have a second course of chemotherapy?

- Yes No

Q3.32. Second course of chemotherapy

Please write 1st of month and year

Q3.33. Was this as part of a Clinical Trial?

- Yes No

Q3.34. What was the treatment?

- Pemetrexed and Cisplatin
- Pemetrexed and Carboplatin
- Pemetrexed as a single drug
- Pemetrexed, Cisplatin and Bevacizumab (Avastin)
- Pemetrexed, Carboplatin and Bevacizumab (Avastin)
- Bevacizumab (Avastin) as a single drug
- Gemcitabine and Cisplatin
- Gemcitabine and Carboplatin
- Vinorelbine
- Any other drugs in a clinical trial
- Any other drugs not in a clinical trial

Q3.35. How many cycles did you complete?

- | | |
|----------------------------|--|
| <input type="checkbox"/> 1 | <input type="checkbox"/> 5 |
| <input type="checkbox"/> 2 | <input type="checkbox"/> 6 |
| <input type="checkbox"/> 3 | <input type="checkbox"/> More than 6, still receiving it |
| <input type="checkbox"/> 4 | |

Q3.36. Did you continue on maintenance treatment?

- Yes No

Q3.37. Did you have a third course of chemotherapy?

- Yes No

Q3.38. Third course of chemotherapy

Please write 1st of month and year

Q3.39. Was this as part of a Clinical Trial?

- Yes No

Q3.40. What was the treatment?

- Pemetrexed and Cisplatin
- Pemetrexed and Carboplatin
- Pemetrexed as a single drug
- Pemetrexed, Cisplatin and Bevacizumab (Avastin)
- Pemetrexed, Carboplatin and Bevacizumab (Avastin)
- Bevacizumab (Avastin) as a single drug
- Gemcitabine and Cisplatin
- Gemcitabine and Carboplatin
- Vinorelbine
- Any other drugs in a clinical trial
- Any other drugs not in a clinical trial

Q3.41. How many cycles did you complete?

- | | |
|----------------------------|--|
| <input type="checkbox"/> 1 | <input type="checkbox"/> 5 |
| <input type="checkbox"/> 2 | <input type="checkbox"/> 6 |
| <input type="checkbox"/> 3 | <input type="checkbox"/> More than 6, still receiving it |
| <input type="checkbox"/> 4 | |

Q3.42. Did you continue on maintenance treatment?

- Yes No

Q3.43. At this current moment in time what of the following best describes you?

- I have had surgery but no other treatment and my disease is stable
- I have never received any treatment and my disease is stable
- I have never received any treatment and my disease is active/progressing
- I am waiting to start my first course of chemotherapy
- I am currently receiving chemotherapy for the first time
- I have previously received chemotherapy once and my disease is stable
- I have previously received chemotherapy once, but my disease is active/progressing
- I am currently receiving treatment (chemotherapy/immunotherapy/targeted therapy) for the second time as my disease is active/progressing

- I have previously received treatment (chemotherapy/immunotherapy/targeted therapy) twice and my disease is stable
- I have previously received treatment (chemotherapy/immunotherapy/targeted therapy) twice, the treatment is now ineffective, and my disease is active/progressing
- I have received 3 or more treatments (chemotherapy/immunotherapy/targeted therapy) and my disease is stable
- I have received 3 or more treatments (chemotherapy/immunotherapy/targeted therapy), the treatment is now ineffective and my disease is progressing

Q3.44. Do you know your current performance status, (known as ECOG), which is scored on a scale of 0 to 4?

- Yes (*if yes, please go to Q3.45*)
- No (*if no, please go to Q3.46*)

Q3.45. What is the status score that has been given to you?

- 0: Fully active, able to carry on all pre-disease performance without restriction
- 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature e.g. light housework, office.
- 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
- 3: Capable of only limited selfcare, confined to bed or chair for 50% of waking hours.
- 4: Completely disabled. Cannot carry out any selfcare. Totally confined to bed or chair.

Q3.46. Your Mesothelioma Nurse will tick the performance score on your behalf

- 0: Fully active, able to carry on all pre-disease performance without restriction
- 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature e.g. light housework, office.
- 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
- 3: Capable of only limited selfcare, confined to bed or chair for 50% of waking hours.
- 4: Completely disabled. Cannot carry out any selfcare. Totally confined to bed or chair.

If you have any further comments you would like to share please email Mesothelioma UK at info@mesothelioma.uk.com

Q3.47. Name of MESO Nurse

- to be supplied by MESO UK
- Unknown

Q3.48. Please enter your unique patient identifier

Q3.49. Name of hospital

You have now completed this questionnaire.

Please confirm if Section 3 has been validated by the Meso UK nurse

- Yes
- No, to be validated later